PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)

Summary

Data regarding optimal treatment for extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae blood-stream infection are lacking. Observational studies show conflicting results when comparing treatment with combination beta-lactam-beta-lactamase inhibitor and carbapenems. The investigators aim to evaluate the effect of definitive treatment with meropenem vs. piperacillin-tazobactam on the outcome of patients with bacteremia due to cephalosporin-non-susceptible Enterobacteriaceae. The investigators hypothesize that piperacillin-tazobactam is non-inferior to meropenem.

Conditions

• Beta Lactam Resistant Bacterial Infection
• Enterobacteriaceae Infections
• Bacteremia

Interventions

DRUG

Piperacillin/tazobactam

4.5 grams QID

DRUG

Meropenem

1 gram TID

Sponsors & Collaborators

• Rabin Medical Center

  collaborator OTHER

• University of Modena and Reggio Emilia

  collaborator OTHER

• Tel Aviv Medical Center

  collaborator OTHER

• Meir Medical Center

  collaborator OTHER

• Soroka University Medical Center

  collaborator OTHER

• The Chaim Sheba Medical Center

  collaborator OTHER

• McGill University Health Centre/Research Institute of the McGill University Health Centre

  collaborator OTHER

• Jewish General Hospital

  collaborator OTHER

• Canadian Institutes of Health Research (CIHR)

  collaborator OTHER_GOV

• Hadassah Medical Organization

  collaborator OTHER

• Rambam Health Care Campus

  lead OTHER

Principal Investigators

• Roni Bitterman, MD · Rambam Health Care Campus

• Mical Paul, MD · Rambam Health Care Campus

• Leonard Leibovici, MD · Rabin Medical Center

• Cristina Mussini, MD · University of Modena and Reggio Emilia

• Noa Eliakim-Raz, MD · Rabin Medical Center, Beilinson Campus

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-05-01

Primary Completion

2027-01-01

Completion

2027-04-01

Countries

• Canada
• Israel

Study Locations